US Patent

US7713938 — Crystalline form of 1-chloro-4-(Î²-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments

Composition of Matter · Assigned to Boehringer Ingelheim International GmbH · Expires 2027-04-15 · 1y remaining

Vulnerability score 22/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a specific crystalline form of the molecule 1-chloro-4-(Î²-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene.

USPTO Abstract

The invention relates to a crystalline form of 1-chloro-4-(Î²-D-glucopyranos-1-yl)-2-[4-((S) -tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.

Drugs covered by this patent

Jardiance (empagliflozin) · Boehringer Ingelheim

Patent Metadata

Patent number: US7713938
Jurisdiction: US
Classification: Composition of Matter
Expires: 2027-04-15
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Boehringer Ingelheim International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.